Category: Prof. Erika Lietzan ⋅ Page 1

Professor Lietzan Presents Paper at Law and Biosciences Workshop

On May 6, Professor Erika Lietzan presented her most recent paper at Stanford Law School, as part of its Law and the Biosciences Workshop. Her paper, Access Before Evidence and the Price of FDA’s New Drug Authorities, explores the costs of error and delay associated with federal government approval of new drugs, as well as costs associated with other less-studied aspects of…

Professor Lietzan Speaks About Top Cases in Food and Drug Law

On May 3, Professor Erika Lietzan spoke at the annual meeting of the Food and Drug Law Institute (FDLI), a nonprofit organization dating to the 1940s that brings together experts from the federal government, industry, the private bar, non-profit organizations, patient and consumer advocates, consulting firms, and academia. Its annual meeting is the premier conference for the food and drug law community…

Professor Lietzan Lectures on the Hatch-Waxman Amendments

Professor Erika Lietzan recently gave a lecture on the Hatch-Waxman Amendments as part of the Mason Judicial Education Program, a division of George Mason University’s Law & Economics Center (LEC). Professor Lietzan lectured for an hour on the Hatch-Waxman Amendments, which created a statutory pathway for approval of generic drugs as well as provisions governing the timing of that approval…

Professor Lietzan Quoted in Article about CBD

Professor Erika Lietzan was quoted recently in a Philadelphia Inquirer story, “Selling CBD in food is illegal, FDA says. So why are so many retailers selling it?,” about the sale of foods and dietary supplements containing CBD, or cannabidiol, which is derived from cannabis. CBD is reputed to have health benefits, and after FDA approved a new drug containing CBD in…

Professor Lietzan Quoted by CBS News on Pharmaceutical Manufacturing Recall

Professor Erika Lietzan was recently quoted by CBS News in a Moneywatch article relating to pharmaceutical manufacturing, “Drugmaker behind ibuprofen recall has history of FDA violations.” Last month New Jersey drugmaker Tris Pharma doubled its recall of infant ibuprofen, and CBS News spoke with Professor Lietzan about the company’s manufacturing history.  She described some of the “red flags” in a…

Professor Lietzan Collaborates on Compassionate Use Research in France and the U.S.

Professor Erika Lietzan is spending six weeks in France at the invitation of the Centre de Recherche sur le Droit International des Marchés et des Investissements (CREDIMI) at Université de Bourgogne. At the end of November, she attended a colloquium at the French Supreme Court concerning the rights of children with anonymous biological parents (due to sperm or egg donation) to learn the identities…

Professor Lietzan Presents at Symposium on Federal Regulation of Cannabis

Professor Erika Lietzan presented her most recently completed article at a symposium on federal regulation of cannabis. The symposium, hosted by the Food and Drug Law Institute, convened academics, scientists from the Food and Drug Administration, lawyers from private practice, and industry developing cannabis-based products, to consider the path forward for a federal regulatory regime. Professor Lietzan’s forthcoming article in the American…

Professor Lietzan Presents at Center for the Protection of Intellectual Property

Professor Erika Lietzan recently presented her current research at the sixth annual fall conference of the Center for the Protection of Intellectual Property, at Scalia Law School, George Mason University.  This year’s conference focused on intellectual property for the next generation of technology. Professor Lietzan focused on fecal microbiota transplants and other therapeutic innovations that begin in the academic clinical setting. Her…

Professor Lietzan Receives ‘Best Lawyer’ honors

Professor Erika Lietzan has been named a “Best Lawyer in America”  in FDA Law and in Biotechnology and Life Sciences Law.  This marks the sixth year in a row for FDA law and the twelfth year in a row for biotechnology law.  The Best Lawyers honor is meant to identify the top 5 percent of practicing attorneys in the United…

Professor Lietzan Speaks at Food & Drug Law Institute’s Annual Conference

On May 4, Professor Erika Lietzan participated in the perennially popular closing session – on significant litigation in 2017 and cases to watch in 2018 – of the Food & Drug Law Institute’s annual conference.  FDLI is the primary professional association for specialists in food and drug law.  The annual meeting brought together more than 900 law professors, practicing lawyers,…